120
Participants
Start Date
August 8, 2019
Primary Completion Date
June 30, 2027
Study Completion Date
December 31, 2027
Pioglitazone 45 mg
patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
Placebo
PATIENTS WILL RECEIVE PLACEBO
ACTIVE_NOT_RECRUITING
University Health System Texas Diabetic Institute, San Antonio
ACTIVE_NOT_RECRUITING
Endocrinology and Diabetes Center, Rambam Medical Center, Haifa
RECRUITING
Dasman Diabetes Institute, Kuwait City
The University of Texas Health Science Center at San Antonio
OTHER